IVA Inventiva S.A.
Inventiva S.A. (IVA) is confirmed to report earnings on September 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Inventiva S.A.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.